Vinay Saluja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vinay Saluja has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Henderik Willem Frijlink
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen, 9713 AV Groningen, The Netherlands
5 shared publications - Wouter Leonardus Joseph Hinrichs
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
5 shared publications A. Huckriede
Department of Medical Microbiology, Molecular Virology Section, University Medical Center and University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands
2 shared publicationsK. Leenhouts
Mucosis BV, Meditech Center, L.J. Zielstraweg 1, 9713 GX, Groningen, The Netherlands
2 shared publicationsM.L. van Roosmalen
Mucosis BV, Meditech Center, L.J. Zielstraweg 1, 9713 GX, Groningen, The Netherlands
2 shared publicationsM.R. Visser
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands
2 shared publications
Latest Publications
- 1 November 2010
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 76 (3) , 470-474
Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles
- 1 November 2010
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 76 (3) , 470-474
Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles
- 1 October 2010
- Published by Taylor & Francis in Human Vaccines
- Vol. 6 (10) , 854-856
Dried influenza vaccines: Over the counter vaccines
Since last year influenza pandemic has struck again after 40 years, this is the right moment to discuss the different available formulation options for influenza vaccine. Looking back to the last 4...
- 1 October 2010
- Published by Taylor & Francis in Human Vaccines
- Vol. 6 (10) , 854-856
Dried influenza vaccines: Over the counter vaccines
Since last year influenza pandemic has struck again after 40 years, this is the right moment to discuss the different available formulation options for influenza vaccine. Looking back to the last 4...
- 1 June 2010
- Published by Elsevier in Journal of Controlled Release
- Vol. 144 (2) , 127-133
A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation
- 1 June 2010
- Published by Elsevier in Journal of Controlled Release
- Vol. 144 (2) , 127-133
A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation
- Open Access
- 8 January 2010
- Published by Springer Nature in The AAPS Journal
- Vol. 12 (2) , 109-116
Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant
Nasal administration of influenza vaccine has the potential to facilitate influenza control and prevention. However, when administered intranasally (i.n.), commercially available inactivated vaccines only generate systemic and mucosal immune responses if strong adjuvants are used, which are often associated with safety problems. We describe the successful use of a safe adjuvant Gram-positive enhancer matrix (GEM) particles derived from the food-grade bacterium Lactococcus lactis for i.n. vaccination with subunit influenza vaccine in mice. It is shown that simple admixing of the vaccine with the GEM particles results in a strongly enhanced immune response. Already after one booster, the i.n. delivered GEM subunit vaccine resulted in hemagglutination inhibition titers in serum at a level equal to the conventional intramuscular (i.m.) route. Moreover, i.n. immunization with GEM subunit vaccine elicited superior mucosal and Th1 skewed immune responses compared to those induced by i.m. and i.n. administered subunit vaccine alone. In conclusion, GEM particles act as a potent adjuvant for i.n. influenza immunization.
- 8 January 2010
- Published by Springer Nature in The AAPS Journal
- Vol. 12 (2) , 109-116
Open AccessIntranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant
Nasal administration of influenza vaccine has the potential to facilitate influenza control and prevention. However, when administered intranasally (i.n.), commercially available inactivated vaccines only generate systemic and mucosal immune responses if strong adjuvants are used, which are often associated with safety problems. We describe the successful use of a safe adjuvant Gram-positive enhancer matrix (GEM) particles derived from the food-grade bacterium Lactococcus lactis for i.n. vaccination with subunit influenza vaccine in mice. It is shown that simple admixing of the vaccine with the GEM particles results in a strongly enhanced immune response. Already after one booster, the i.n. delivered GEM subunit vaccine resulted in hemagglutination inhibition titers in serum at a level equal to the conventional intramuscular (i.m.) route. Moreover, i.n. immunization with GEM subunit vaccine elicited superior mucosal and Th1 skewed immune responses compared to those induced by i.m. and i.n. administered subunit vaccine alone. In conclusion, GEM particles act as a potent adjuvant for i.n. influenza immunization.